East China medicine class 1 antitumor drug mehuatinib applied for clinical acceptance
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the information on CFDA website, the clinical application of the first class antitumor drug of East China medicine, mehuatinib API and tablet, has been accepted East China medicine is the leader of immune preparation and digestive system medicine in China, and anti-tumor, anti severe infection and cardiovascular fields are the new areas that the company will focus on in the next three years According to the public information, TiNi is a new kind of biological targeted tumor drug Currently, the common TiNi anti-tumor drugs in the Chinese market include: gefitinib, imatinib, imatinib mesylate, nilotinib, sunitinib and lapatinib CFDA shows that there is no approved listing of mehuatinib in China, and only one East China pharmaceutical company has applied for clinical research and development.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
